Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study

Ricardo-Silgado, Maria L.; Singh, Sneha; Cifuentes, Lizeth; Decker, Paul A.; Gonzalez-Izundegui, Daniel; Moyer, Ann M.; Hurtado, Maria D.; Camilleri, Michael; Bielinski, Suzette J.; Acosta, Andres

doi:10.1186/s12916-022-02433-x

Table 5 Multiple regression variate analysis. Total body weight gain by obesity class and CYP phenotype in participants prescribed with citalopram, paroxetine, fluoxetine, and sertraline

From: Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study

CYP2C19
		Model 1				Model 2				Model 3
		Poor/intermediate metabolizer		Rapid/ultra-rapid metabolizer		Poor/intermediate metabolizer		Rapid/ultra-rapid metabolizer		Poor/intermediate metabolizer		Rapid/ultra-rapid metabolizer
		PE	p-value^*	PE	p-value^*	PE	p-value⁺	PE	p-value⁺	PE	p-value⁺⁺	PE	p-value⁺⁺
Citalopram	TBWG 6 mths, %	1.7 (0.5)	0.001	-1.2 (0.5)	0.01	1.7 (0.6)	0.001	-1.2 (0.5)	0.02	1.7 (0.5)	0.001	-1.2 (0.5)	0.02
Sertraline	TBWG 6 mths, %	-0.03 (0.4)	0.94	0.7 (0.4)	0.08	0.01 (0.4)	0.99	0.7 (0.4)	0.10	0.01 (0.4)	0.99	0.7 (0.4)	0.11
CYP2D6
		Model 1				Model 2				Model 3
		Poor/intermediate metabolizer		Rapid/ultra-rapid metabolizer		Poor/intermediate metabolizer		Rapid/ultra-rapid metabolizer		Poor/intermediate metabolizer		Rapid/ultra-rapid metabolizer
		PE	p-value^*	PE	p-value^*	PE	p-value⁺	PE	p-value⁺	PE	p-value⁺⁺	PE	p-value⁺⁺
Paroxetine	TBWG 6 mths, %	-0.3 (1.4)	0.82	-0.3 (0.7)	0.71	-0.4 (0.7)	0.61	-0.1 (1.4)	0.96	0.4 (0.7)	0.61	-0.1 (1.4)	0.96
Sertraline	TBWG 6 mths, %	0.1 (0.6)	0.76	-0.3 (1.2)	0.80	0.1 (0.6)	0.89	-0.3 (1.2)	0.77	0.1 (0.6)	0.91	0.3 (1.2)	0.77
Fluoxetine	TBWG 6 mths, %	-0.6 (1.1)	0.58	1.2 (2.2)	0.57	-0.6 (1.1)	0.57	1.3 (2.2)	0.50	-0.6 (1.1)	0.60	1.2 (2.2)	0.57
CYP2C9
		Model 1				Model 2				Model 3
		Poor/intermediate metabolizer		Rapid/ultra-rapid metabolizer		Poor/intermediate metabolizer		Rapid/ultra-rapid metabolizer		Poor/intermediate metabolizer		Rapid/ultra-rapid metabolizer
		PE	p-value^*	PE	p-value^*	PE	p-value⁺	PE	p-value⁺	PE	p-value⁺⁺	PE	p-value⁺⁺
Fluoxetine	TBWG 6 mths, %	0.3 (0.3)	0.33			0.3 (0.6)	0.33			0.3 (0.3)	0.39

p-value: multiveriate linear regression with normal metabolizar as reference group
^* model including BMI
⁺ model including BMI and age
⁺⁺ model including BMI, age and sex
Abbreviations used: BMI body mass index; PE parameter estimates, TBWG Total Body Weight Gain

Back to article page

ISSN: 1741-7015

Contact us

Submission enquiries: bmcmedicineeditorial@biomedcentral.com
General enquiries: info@biomedcentral.com

BMC Medicine

Contact us